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Abstract
Background: Derivative based a-priori structural identifiability analyses of
mathematical models can offer valuable insight into the identifiability of model
parameters. However, these analyses are only capable of a binary confirmation of the
mathematical distinction of parameters and a positive outcome can begin to lose
relevance when measurement error is introduced. This article presents an integral
based method that allows the observation of the identifiability of models with
two-parameters in the presence of assay error.
Methods: The method measures the distinction of the integral formulations of the
parameter coefficients at the proposed sampling times. It can thus predict the
susceptibility of the parameters to the effects of measurement error. The method is
tested in-silico with Monte Carlo analyses of a number of insulin sensitivity test
applications.
Results: The method successfully captured the analogous nature of identifiability
observed in Monte Carlo analyses of a number of cases including protocol
alterations, parameter changes and differences in participant behaviour. However,
due to the numerical nature of the analyses, prediction was not perfect in all cases.
Conclusions: Thus although the current method has valuable and significant
capabilities in terms of study or test protocol design, additional developments would
further strengthen the predictive capability of the method. Finally, the method captures
the experimental reality that sampling error and timing can negate assumed parameter
identifiability and that identifiability is a continuous rather than discrete phenomenon.
1. Background
A number of physiological phenomenon have been modelled by formulating mathemati-
cal representations of the relevant interactions. These models frequently incorporate
variable parameters that can be identified to match the model representation to the
observed behaviour. The value of these parameters is then used to characterise or quan-
tify the response. However, with complex or large models, variable parameters can be
selected that seem mathematically distinct, but in reality define the same observable
effect and identification failure is certain. Thus, model identifiability analyses are used to
test the selection of model parameters and ensure that they are mathematically distinct.
Approaches for the analysis of model identifiability typically assume continuous per-
fect input data [1-3]. However, these derivative-based identifiability methods can
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reproduction in any medium, provided the original work is properly cited.produce false assurances of identifiability. Recent dissatisfaction with the classical algo-
rithms has resulted in the development of new methods that recognise assay error and
discrete measurements as critical to identifiability [4,5]. The limitation of discrete data
that is often subject of assay error often causes parameter trade-off [6-9] and thus lim-
itation of the identified metrics clinical value. Thus, not only should a model be
checked for identifiability in the classical a-priori sense, but the susceptibility of para-
meters to mutual interference should also be tested.
For example, the Minimal Model of insulin sensitivity [10] has been shown to be
identifiable using such methods [11-13]. However, with discrete data that is subject to
assay error, parameter identification has sometimes failed [6,7,14]. Numerous Bayesian
techniques have had success in limiting this failure [7,15-17], but they tend to force
the parameters to diverge away from their true least square values, limiting the rele-
vance of the model and exaggerating the influence of population trends on an indivi-
dual test’s identified parameter values. Thus, widespread clinical application of these
models has been limited by the ambiguity of results.
This article presents a novel graphical method for identifiability analysis that allows
an identifiability analysis with consideration of noise and assay error. Furthermore, the
method highlights areas for potential improvements to protocols and sampling times
that would improve practical identifiability. At this stage of development, the method
is limited to first-order, two-parameter models that allow a separation of parameters,
but are typical of those found in pharmacokinetic (PK) and pharmacodynamic (PD)
modelling.
2. Method and Study Design
T h ep r o p o s e dm e t h o dw i l lb ee v a l u a t e din-silico using clinically validated models of
insulin kinetics and the dynamic between insulin concentration and glucose decay. The
method’s ability to predict the variation behaviour of identified parameters in a Monte
Carlo analysis will be tested.
2.1 Proposed method process
To evaluate identifiability of a model, the integral formulations of the parameters are
evaluated using an estimated test stimulus response. Thus, the method cannot be used
in complete ignorance of the expected behaviour of the test participant. In particular,
the approximate shape of the species concentrations as a result of the test protocol
must be estimated, (this is a reasonable assumption in most PK/PD studies). The speci-
fic steps are illustrated using a generalised function:
˙ X = f(X,Y,C,D,a,b) (i)
where: X is a measured species with a discrete resolution, Y is a species that is co-
dependent with X and is not measureable, C and D are independent known input pro-
files, and a and b are unknown model parameters
1. Rearrange governing equation to create a first order differential equation with
separated parameters in terms of a-priori, constant and measurable concentration
terms
˙ X = af1(X,Y,C) + bf2(X,Y,C) + D (ii)
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Xi − X0 = a
  i
0
f1(X,Y,C)dt + b
  i
0
f2(X,Y,C)dt +
  i
0
Ddt (iii)
where: i is each measured sample time after the first.
3. Evaluate the integral of the coefficients of each parameter between 0 and each
proposed sample time using an assumed participant response to the test stimulus.
˜ a =
  i
0
f1(X,Y,C) ˜ b =
  i
0
f2(X,Y,C) (iv)
4. Divide the resulting values by their respective means to normalise the coeffi-
cients.
  a = ˜ a/¯ ˜ a
 
b = ˜ b/¯ ˜ b (v)
5. Subtract one set of coefficients from the other and define the 2-norm of the
result (||Δ||2).
|| ||2 = ||
  a −
 
b||2 (vi)
6. Any distinction at all between the coefficients would imply identifiability (i.e. if ||
Δ||2 ≠ 0). In reality, the effect of assay error on parameter identification is inversely
proportional to the magnitude of this distinction (and proportional to the magni-
tude of any assay error (ε)):
Variability = μ
ε
|| ||2
(1)
where: μ is a proportionality factor that incorporates factors such as the relative con-
tribution of the parameter to the derivative of the relevant species concentration in the
governing differential equation, and the absolute magnitude of the noise at the sampled
times in relation to the relative magnitude of the parameter coefficient.
Thus, the method cannot accurately predict the coefficient of variation that a Monte
Carlo analysis may find. However, it can predict the change of variation that might be
observed when changes are made to the test sampling or stimulus protocols.
2.2 The dynamic insulin sensitivity and secretion test (DISST) model
2.2.1 Insulin pharmacokinetics
Initially, a validated model of insulin PKs [18,19] is used to evaluate the method
described, and is defined:
˙ I = −nkI − nL
I
1+αII
−
nI
VP
(I − Q)+xLUN +
UX
VP
(2)
˙ Q =
nI
VQ
(I − Q) − nCQ (3)
where: equation nomenclature is defined in Table 1
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define the PKs of insulin due to test stimulus [18,20]. The model assumes that plasma
insulin (I) is sampled. A traditional derivative based identifiability analysis of the model
presented in Equations 2 and 3 using Ritt’s pseudo-division algorithm [1,21] is pre-
sented in Appendix 1.
2.2.2 Pharmaco-dynamics of glucose and insulin
The parameters of the glucose-insulin PDs can also offer insight into the identifiability
of parameters. The DISST model of glucose-insulin PDs is defined [18,19]:
˙ G = −pG(G − Gb) − SI(GQ − GbQb)+
PX
VG
(4)
where: equation nomenclature is defined in Table 2.
Although the structural identifiability of Equation 4 is trivial it is also presented in
Appendix 1.
2.3 Participants
Parameter values from two participants of the pilot investigation of the DISST [18] are
used to generate in-silico simulated data to construct and demonstrate the method
proposed here. In-silico data is used in this analysis because it allows protocols to be
changed to illustrate the impact on identifiability. The participant characteristics that
are summarised in Table 3 represent the extremities of the range of cases encountered
in typical research studies of insulin sensitivity.
Table 1 Nomenclature from Equations 2 and 3
Symbol definition units
I Plasma insulin concentration mU/L
Q Interstitial insulin concentration mU/L
UN Endogenous insulin production rate profile mU/L/min
UX Exogenous insulin bolus mmol
nK Renal clearance of plasma insulin 1/min
nL Hepatic clearance of plasma insulin 1/min
nC Insulin clearance to cells 1/min
nI Transition of insulin between plasma and interstitium L/min
aI Saturation of hepatic insulin clearance L/mU
xL First pass clearance of insulin 1
VP Distribution volume of plasma insulin L
VQ Distribution volume of interstitial insulin L
Table 2 Nomenclature from Equation 4
Symbol definition units
G Glucose concentration mmol/L
Q Interstitial insulin concentration mU/L
Gb Basal glucose concentration mmol/L
Qb Basal interstitial insulin concentration mU/L
pG Glucose dependant glucose clearance 1/min
SI Insulin sensitivity L/mU/min
PX Exogenous glucose bolus mmol
VG Glucose distribution volume L
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The simulated protocol is similar to the DISST test; a 10 g glucose bolus is adminis-
tered at t = 7.5 and a 1 U insulin bolus at t = 17.5. The test duration is 60 minutes
with a 5 minute sampling frequency. The UN profile is defined as a step function with
three stages including basal, first and second phase production rates. The first phase of
insulin production has a five-minute duration and begins with the glucose bolus. Simu-
lations of plasma and interstitial insulin are completed using Equations 2 and 3, the
parameter estimation equations from [22], nL and xL values from Table 3 and an aI
value of 0.001 L/mU. Glucose is simulated using Equation 4 and the interstitial insulin
profile obtained in the evaluation of Equations 2 and 3.
2.5 Iterative integral method
The analyses of this study will use the iterative integral method to identify parameters
[20,23]. Although the method has been presented [20], it is repeated in brief in Steps
1-5 below:
1. The method converts the model governing equations to their integral
formulation.
2. The parameter coefficients and the remainder terms are evaluated between t =0
and the sample times.
3. The coefficients form the LHS of a matrix equation in terms of the parameters,
while the remainder terms form the RHS. This matrix is evaluated to get parameter
values.
4. These parameter values are used to update the coefficient evaluations in step 2,
which enables a more accurate matrix equation in step 3.
5. Step 4 is iterated until convergence is achieved.
2.6 Analysis
A series of parameter and sampling scenarios were analysed using the models pre-
sented in a Monte Carlo analysis. Clinically measured physiological parameters of the
NGT participant presented in Table 3 were used to define simulated responses to the
test protocol described in Section 2.4. Samples were obtained from the simulated pro-
files at the defined times. Each iteration of the Monte Carlo analysis adds normally dis-
tributed assay error (the error magnitude is defined within each section). 100 iterations
are used for each analysis with parameter identification by the iterative integral
method. Only simulated profiles from the NGT participant are used until Section
3.2.2. Each scenario will present the mean value of those identified in the Monte Carlo
Table 3 Anatomical and identified parameter values
Glucose tolerance Sex Age BMI UN
† I clearance VG SI
Ub U1 U2 nL xL
NGT M 22 21.5 26.6 487.7 9.7 0.218 0.797 9.75 20.95
IGT* F 57 33.9 115.5 233.6 150.7 0.064 0.822 13.35 2.236
Anatomical and identified parameter values (using the iterative integral method) of normal-glucose tolerant (NGT) and
impaired glucose tolerant (IGT) participants of the DISST pilot investigation. (* The IGT participant had suspected, yet un-
diagnosed, type 2 diabetes at the time of testing,
† Ub,U 1 and U2 represent the basal, first and second phases of insulin
production, respectively [mU/min]).
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iation (CV) of each identified parameter (i.e. A mean of 1 and standard deviation of 0
implies perfect identification). The CV values are the paramount indicator of para-
meter trade-off during identification. The CV values are thus was compared to the ε/||
Δ||2 value defined using the methods of Section 2.1 to obtained values for μ that line-
arise Equation 1.
2.7 Cases tested
A series of indicative cases will be investigated to show how the selection of model
parameters, sample placement, participant behaviour and protocol dosing can have an
effect on model identifiability.
￿ The insulin pharmacodynamic model will include five variable parameters to be
identified to confirm the robustness and convexity of the iterative integral method,
and to confirm the findings of the traditional derivative-based identifiability
analysis.
￿ Parameter interference of nL and nK will be analysed. The nature of identifiability
will be explored by alteration of the aI term that moderates the denominator of nL
in Equation 2.
￿ The effect of sample selection on parameter identification of nT and VP will be
measured. (nT is the addition of nL and nK).
￿ The effects of sample omissions on SI and VG identification are measured.
￿ The disparity of parameter identifiability in insulin resistant and sensitive indivi-
duals will be assessed using pG and SI as variable model parameters.
￿ The protocol proposed in Section 2.4 will be altered to see if the identifiability of
insulin resistant participants can be improved.
￿ Measured samples that the proposed method claims are not valuable to stable
identification are ignored and the identification process is repeated to confirm the
prediction.
All cases will be tested with 1% and 3.5% normally distributed noise added to the vir-
tually obtained data (to a maximum of 3 standard deviations).
3. Results
3.1 Analysis of the insulin pharmacokinetic model
3.1.1 Confirmation of global model identifiability
When the sampled data is used in the iterative integral method to define nL, nK, nI/VP,
xL and VP as parameters, convergence to the simulation values occurs (Figure 1). This
confirms the traditional identifiability analysis of Equations 2 and 3 in Appendix 1.
However, when 1% normally distributed noise is added to the simulated data, para-
meter values do not converge to simulation values (Figure 1). When the sample noise
is increased to 3.5%, which is more indicative of actual measurement noise encoun-
tered clinically, parameter convergence is significantly biased. Hence despite proven
(no noise) structural identifiability, the addition of assay error or noise yields corrupted
or potentially unidentifiable results.
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To understand why the addition of noise disables the identification, the case of inter-
ference between nK and nL is tested. In this analysis, all parameters of Equations 2 and
3 are set as constants and only nL and nK are identified as parameters. From the ana-
lyses in Appendix 1 and Section 3.1.1, parameter convergence is assured for the noise-
less case. However, for the 1% and 3.5% noise cases parameter interference causes
considerable parameter divergence in the value of the identified parameters compared
to the actual values used in-silico. The Monte Carlo analysis described in Section 2.6 is
used to evaluate these parameters in the presence of noise and the results are shown
in Table 4.
The matrix equation used by the iterative integral method is a re-arrangement of
Equation 2 and is in the form:
−nk
  i
0
Idt − nL
  i
0
I
1+αII
dt
= Ii − I0 +
nI
Vp
  i
0
(I − Q)dt − xL
  i
0
UNdt +
  i
0
UX
Vp
dt
(2a)
where: i= 5, 10, 15, ..., 60 minutes, matching sampling times.
Thus, the value of the ||Δ||2 term can be obtained for this model and sampling pro-
tocol as:
|| ||2 =
   
   
   
 
 
⎛
⎜
⎝
  i
0 Idt
1
n
   i
0 Idt
⎞
⎟
⎠ −
⎛
⎜
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  i
0
I
1+αII
dt
1
n
   i
0
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Figure 1 Convergence of 5 parameter case.M e a na b s o l u t ep e r c e n t a g ee r r o rb e t w e e nt h es i m u l a t i o n
and identified parameters in the presence of 0%, 1% and 3.5% random assay error, with respect to
iterations of the iterative integral identification approach.
Table 4 Variation in identified nK and nL values
Noise 0% 1% 3.5%
Saturation aI = 0.001 aI = 0.05 aI = 0.001 aI = 0.05 aI = 0.001 aI = 0.05
nK 1(0) 1(0) 0.952(0.297) 0.999(0.017) 0.946(0.836) 1.004(0.059)
nL 1(0) 1(0) 1.035(0.214) 1.001(0.008) 1.041(0.595) 1.000(0.028)
The normalised parameter variation (mean(CV)) when nK and nL are identified model parameters with distinct simulated
assay error and values for aI. (1(0) indicates perfect convergence to the simulation value).
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Page 7 of 20However, Table 4 shows that if aI is increased significantly to 0.05 L/mU, an arbitrarily
chosen value that is not necessarily representative of physiology [24], parameter conver-
gence is more stable. The ||Δ||2 term can be re-identified with the exaggerated aI value.
|| ||2 =
   
   
   
 
 
⎛
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⎝
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0 Idt
1
n
   i
0 Idt
⎞
⎟
⎠ −
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⎜
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⎝
  i
0
I
1+αII
dt
1
n
   i
0
I
1+αII
dt
⎞
⎟
⎟
⎠
   
   
   
 
 
2
=0 . 4 6 4
Thus, the parameters identified with the exaggerated aI term should have approxi-
mately 15 times smaller variability than those identified with the accepted aI value.
Table 4 shows the effect of the aI distinction on the identified parameter values.
Table 4 shows the distinction between the effects of noise on identified parameters
when the aI term is changed. Although the 0% noise case indicates that the parameters
are uniquely identifiable, at 1% noise the variation in the identified values limits their
clinical viability. At 3.5% noise, which may be expected in a real clinical setting, the
parameters are no longer uniquely identifiable. This is illustrated by the very large CVs
of the parameters. However, when the aI term is significantly increased, unique iden-
tifiability is once again possible, even with 3.5% noise. The mean ratio of variation
caused by the disparate aI values was approximately 1:20. This is larger than the ratio
predicted by the method (1:15), but still represents a positive outcome in terms of pre-
dicting the relative magnitude of the change.
The reason for this outcome can be observed in the increased contrast between integral
formulations of the parameter coefficients. The contrast is shown graphically in Figure 2.
The difference between the curves at the sample times indicates the identifiability of
the model parameters in this two-parameter case. Thus, when the saturation term is
increased, the coefficients of the parameters are more distinct and identifiability is
increased. Despite the positive findings of the typical identifiability analysis, a
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Figure 2 Renal and hepatic clearance coefficient integrals. The distinctions between the integral form
of the hepatic and renal clearance coefficients when the standard (left) and exaggerated (right) aI values
are used.
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Page 8 of 20saturation value of 0.001 L/mU causes nK and nL to become uniquely un-identifiable in
a real clinical setting. This outcome may be considered as an elementary finding that
should be inferred with a quick observation of Equation 2. However, it points to a fail-
ing of typical a-priori identifiability tests that this approach can negate with a quick
graphical analysis.
T h ef i n d i n g so ft h i sa n a l y s i sa l s os h o wt h a tt h ef u n c t i o n a le f f e c t so fnL and nK on
insulin concentration in Equation 2 are so similar that there would be a negligible
effect if the terms are combined. As such, further analysis of this model will use a
combined nL and nK term (nT) without the saturation term, which is negligible except
at extremely high insulin concentrations. Equation 2 is thus redefined in Equation 5:
˙ I = −nTI −
nI
VP
(I − Q)+xLUN +
UX
VP
(5)
3.1.3 Plasma insulin distribution volume and insulin clearance identifiability
To identify nT and Vp the form of the governing matrix equation is:
VP
  i
0
(nI(Q − I)+UX)dt − nT
  i
0
Idt = Ii − I0 − xL
  i
0
UNdt (5a)
where: VP =1 / Vp
As with the nK and nL analysis, the 0% noise case exactly reproduced the simulation
values. Figure 3 shows the coefficients of the two parameters and three sampling pro-
tocols. In this case, Protocol 1 uses the 5 minutely sampling defined in Section 2.4.
However, Protocol 2 uses samples at t = 0, 15, 20, and 60, and Protocol 3 uses samples
at t = 0, 5, 45, and 60 minutes. Thus, Protocol 1 requires 13 samples while both proto-
col 2 and 3 only require four samples.
The ||Δ||2 terms can be defined for each of these protocols (Table 5) and the coeffi-
cients are displayed graphically in Figure 3.
The ||Δ||2 values indicate that Protocol 3 will be comparatively unable to reproduce
the simulation values. Contrary to the expected result that parameter identification is
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Figure 3 Plasma distribution volume and inuslin clearance coefficient integrals. Parameter coefficient
distinctions using the three similar clinical protocols with distinct sampling regimens.
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Page 9 of 20best with frequently sampled Protocol 1, the method predicts that the sparsely sampled
Protocol 2 will be slightly more accurate.
Table 6 shows the parameter convergence and variability for the exact same model
with the three different sampling protocols.
It is evident that although Protocols 2 and 3 contain the same number of samples,
the resolution of the identified parameters is considerably reduced in Protocol 3. In
effect, Vp was un-identifiable with Protocol 3. This result occurs because of the lack of
distinction in the coefficients of the parameters at the sample times as indicated in
Table 5 and Figure 3.
Thus, the method predicted the poor performance of the third protocol while it pre-
dicted much lower variability for both Protocols 1 and 2. However, it also suggests
that Protocol 2 would improve slightly upon Protocol 1, which was not the case as
both protocols performed equally in terms of parameter identifiability. It is expected
that it’s equality of variance is an artefact of the normalisation as a function of mean
coefficient at the sample value, artificially lowering the magnitude of the ||Δ||2 terms
in Protocol 1.
Overall, these findings highlight the inefficiency, extreme clinical burden and inten-
sity of frequent sampling in contrast to well-positioned and infrequent sample timing.
More specifically, Protocol 1 used 9 more samples than Protocol 2 with significant
added clinical intensity and assay cost (
~200% more!) for absolutely no information
gain. This outcome was successfully predicted by the identifiability analysis method
presented.
3.2 Analysis of the glucose PD model
Equation 4 will be used in the analysis of identifiability of terms frequently used to
model the PDs of insulin and glucose. All analyses in this section will simulate insulin
concentration profiles for the plasma and interstitium only once for each Monte Carlo
analysis. Thus for clarity and simplicity, it is assumed that insulin is not subject to
assay error here. Furthermore, while glucose assay error from a blood gas analyser is
approximately 2%, errors of 1% and 3.5% will be used for consistency with Section 3.1.
As such, the resultant coefficients of variation should not be considered fully applicable
clinically, but merely as an indication of parameter trade-off during identification. The
Monte Carlo analysis method with the NGT participant described in Section 2.3 is
Table 5 ||Δ||2 values from three sampling protocols defined in Section 3.1.3
||Δ||2
Protocol 1 0.731
Protocol 2 0.990
Protocol 3 0.045
Table 6 Protocol dependence of identified nT and VP values
Noise 1% 3.5%
Protocol 1 2 3 1 2 3
nT 1(0.004) 1(0.003) 0.973(0.012) 1.003(0.012) 1.001(0.014) 0.958(0.045)
VP 1.001(0.014) 0.995(0.012) 1.231(0.175) 0.999(0.047) 0.995(0.051) 1.190(0.463)
Normalised mean and (CV) of the identified values.
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Page 10 of 20repeated for the glucose PD model. The IGT participant will be used in tandem with
the NGT participant from Section 3.2.2.
3.2.1 Insulin sensitivity and distribution volume
Use of the DISST model typically entails the identification of SI and VG in Equation 4
[18,20,25]. As such, this case is tested using the proposed method and three potential
sampling protocols. Specifically, Protocol 1 uses the 5-minute sampling resolution
described in Section 2.4, while Protocols 2 and 3 use 10 and 20-minute resolutions,
respectively. Figure 4 and Table 7 indicate that these parameters are uniquely identifi-
able in the presence of measurement noise given a surprisingly small number of data
points.
Table 7 shows that parameter stability is generally very high even in a sparsely
sampled data set with a relatively high level of noise. This result was expected due to
the relatively large difference in the coefficient integrals shown in Figure 4 for each of
the sampling protocols. Thus, like the case of VP and nT, intelligent sample timing can
significantly reduce clinical burden and study cost with negligible loss of information.
Furthermore, the proposed method successfully predicted this outcome.
3.2.2 Insulin sensitivity and glucose dependent decay
Model-based studies of insulin sensitivity frequently identify a parameter synonymous
with pG in addition to SI and VG as parameters when using the Minimal Model [10] or
similar. However, although these parameters are mathematically distinct, they are known
to trade-off during identification and practical identifiability is not generally assured. It has
been reported that these issues can be exacerbated for insulin resistant (IR) individuals
[7,8]. Thus, the second, IGT participant defined in Table 3 will also be analysed.
Some insight into the parameter trade-off during identification of dynamic test data
can be seen in Figure 5 that contrasts the integral formulations of the parameter coeffi-
cients based on glucose tolerance status. The contrasting shape of the integral formula-
tions of the parameter coefficients is best observed in the pG coefficient. The pG
coefficient is the only term in Equation 4 that could possibly become negative. Thus,
the integral of the coefficient can form a convex shape that contrasts well with the
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Figure 4 Insulin sensitivity and glucose distribution volume coefficient integrals. Distinction between
the integral of the coefficients of the parameters of Equation 5 when differing sampling resolutions are
used.
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Page 11 of 20coefficient of SI as seen for the NGT participant in Figure 5. However, the negative
coefficient of pG can only occur when the participant’s glucose concentration goes
below the basal concentration. Thus, as only NGT participants achieve such concentra-
tion reductions in typical dynamic insulin sensitivity tests, the parameter identifiability
of IR participants is impaired in comparison. In particular, Figure 5 (right) shows mini-
mal difference and a much smaller ||Δ||2 value for this IR individual indicating increas-
ing potential for parameter trade-off in the identification process and loss of effective
identifiability. This is despite an identical test protocol and model.
As mentioned, this limitation of the Minimal Model has been reported, but not
explained in the literature until now.
Table 8 shows the parameter error when the 60 minute 10-minute sampling protocol
is used.
It is apparent that the insulin resistant individual’s parameter identifiability is much
lower than the NGT participant despite the identical PD model, test protocol and
identification process. Table 8 highlights this result, as well as the increasing loss of
identifiability as assay error increases. This is in accordance to published findings and
the proposed method’s prediction.
3.2.3 A hypothetical protocol to enable pG identification in dynamic tests
To forcibly remove this ambiguity introduced by the comparable coefficients of the IR
individual, the protocol of the DISST could be altered. After an initial observation of
Table 7 Sample resolution dependence of identified SI and VG values
Noise 1% 3.5%
Protocol 1 2 3 1 2 3
SI 1.001(0.007) 1.002(0.008) 1(0.016) 1.002(0.028) 1.002(0.033) 1.010(0.054)
VG 1(0.012) 1(0.014) 1.001(0.029) 0.998(0.046) 1.001(0.049) 0.990(0.087)
The normalised mean and (CV) of the glucose PD parameter values from the three proposed sampling resolutions.
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Figure 5 Insulin sensitivity and glucose dependent uptake in NGT and IR individuals. The disparity
between normo-glucose tolerant and insulin resistant individuals in terms of the distinction of the integral
formulations of the coefficients of SI and pG.
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duced to ensure that the participant’s glucose concentration is maintained approxi-
mately 0.5 mmol/L below the basal concentration. Such a protocol may include an
extension of the protocol described in Section 2.4 wherein a period of slight hypogly-
caemia is achieved for each participant with a series of participant-specific insulin
boluses administered with feed-back control.
To allow a fair comparison between the variability of the parameters of the proposed
protocol and the protocol used in Section 3.2.2 the sampling regimen and test duration
will be maintained. Thus, the additional insulin is administered as a bolus t =3 2 . 5
minutes. In a clinical setting, the magnitude of the bolus would be participant-specific
and dependent on the glucose concentration response alone (as glucose can be assayed
in real-time). Note that this task would be very difficult and potentially dangerous in a
regular clinical setting. In particular, the amount of insulin required would vary
between participants, and must be estimated in ignorance of endogenous insulin pro-
duction. This may cause a high incidence of potentially harmful hypoglycaemia. This
protocol is only mooted to illustrate the ability of the method, and in reality the intro-
duction of additional insulin could be applied slowly and safety would be assured.
For the case of the IR participant presented here, reducing glucose sufficiently would
require a 3U bolus at t = 32.5 minutes.
The proposed protocol would alter the shapes of the integral of the parameter coeffi-
cients for the resistant individual. In doing so, it is hypothesised that it would increase
the distinction between these curves to avoid the similarity seen in Figure 5 (right) to
ensure identifiability. The ||Δ||2 value obtained for the IGT participant and the updated
protocol indicates a reduction in variability ratio of approximately 1:2.2. Figure 6
contrasts with Figure 5 (right) as it shows how the added bolus significantly increases
the distinction between the coefficients of the identified parameters. Table 9 shows the
outcomes of this analysis.
Although the inhibitive CV values for the parameters indicate that the proposed pro-
tocol could not be used clinically, the variability decreased in the order predicted by
the identifiability method presented. The hypothetical protocol presented has con-
firmed the reasons discussed for the poor parameter identification observed in many
clinical studies which utilise these two competing parameters [7,8]. Furthermore, it
demonstrates a limitation of traditional identifiability methods, which provide an eva-
luation of identifiability in ignorance of probable participant behaviour or test protocol
design.
The protocol presented would be virtually impossible to apply clinically in the 60
minute duration as it is shown here. However, this analysis was limited by the need for
a comparable duration and sampling regimen to Section 3.2.2. The method could thus
be used to define similar protocols that could yield data that enables unique identifica-
tion of these parameters. If such protocols are pursued, they would most likely require
Table 8 Participant dependence of identified SI and pG values
Noise 1% 3.5%
Participant NGT IR NGT IR
SI 1(0.008) 1.001(0.161) 0.998(0.032) 0.876(0.449)
pG 1.009(0.320) 0.959(0.756) 1.109(0.802) 1.573(1.244)
Normalised mean and (CV) values of the identified.
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Page 13 of 20two sections in a much longer test. The first section would involve the protocol
defined in Section 2.4, and would be followed immediately by an infusion of insulin
designed to safely bring the participant’s glucose concentration to 0.5 mmol/L below
the basal level. Robust results would be most assured if the participant’s glucose con-
centration was maintained below this level for approximately 30 minutes, and thus, the
protocol would most likely require about 2 h o u r s .H o w e v e r ,as t a b l er e s u l tb o t hi n
terms of SI and pG would be generally assured.
3.2.4 Removal of redundant points
The t = 40 minute sample in Figure 5 (left) and t = 30 in Figure 5 (right) show vir-
tually no distinction between the coefficients of either profile. Thus, according to the
theory presented, it should provide no value to the identification process. To test this,
the analysis of Section 3.2.2 is repeated with these samples removed. Figure 7 shows
how the omitted data point do not significantly alter the distinction shown in Figure 5
(Section 3.2.2). Table 10 shows how the identified parameters were affected by the
omission of data that the method implied were redundant.
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Figure 6 Effect of an alternative protocol to maximise parameter distinction in IR individuals.
The effect of the added insulin bolus on the distinction of the coefficient integrals of pG and SI for the IR
participant.
Table 9 Effect of the added insulin bolus on the identifiability of SI and pG from the IR
participant
Noise 1% 3.5%
SI 1.002(0.029) 0.996(0.070)
ΔSI +0.001(-0.132) +0.120(-0.379)
pG 0.989(0.369) 0.992(0.969)
ΔpG +0.030(-0.387) -0.581(-0.275)
Parameter convergence from the proposed hypothetical protocol. ΔSI and ΔpG show the change between these values
and those from the same individual presented in Section 3.2.2. The bold ΔCV values are the critical finding of this
analysis.
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assumed to be obsolete had little effect on the outcome of the identification process.
Most changes were very small and only those for the particularly un-stable parameters
showed any significant changes.
3.3 The value of μ
The value of μ in Equation 1 can be used to enable prediction of the probable variabil-
ity in the identified parameters in a Monte Carlo simulation. Thus, the effects of proto-
col changes on the parameter identifiability can be predicted without the need for
numerous Monte Carlo simulations. To identify the value of μ linear relationships
between the CV values obtained and the ε/||Δ||2 values are defined. As noiseless iden-
tifiability of all models has been proven, the y-intercept can be assumed at zero, and
μ can be identified using Equation 6:
μ =
1
N
  CV
(ε/|| ||2)
(6)
Figure 8 shows the adherence of μ to linear relationships while Table 11 shows the
value of μ for the different parameters.
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Figure 7 Effect of omitting assumed negligible samples. The coefficient comparison in alternative
sampling protocols that omit the samples that according to Figure 5 have almost negligible value in terms
of identifiability due to the very small magnitude of distinction at the sample times.
Table 10 The effect of targeted sample omission
Noise 1% 3.5%
Participant NGT IR NGT IR
SI 0.999(0.010) 0.960(0.182) 1(0.029) 0.852(0.496)
ΔSI -0.001(+0.002) -0.041(+0.021) +0.002(-0.003) -0.024(+0.047)
pG 1.019(0.360) 1.152(0.693) 1.400(0.762) 1.231(1.156)
ΔpG +0.010(+0.040) +0.193(-0.063) +0.311(-0.040) +0.342(-0.088)
Parameter normalised mean and (CV) values of identified parameters with the omission of the assumed negligible data
points. ΔSI and ΔpG are the change in values between this analysis and Section 3.2.2. The bold ΔCV values are the key
finding of this analysis.
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It can be observed that no single value for μ can be applied across all models and
that different parameters are considerably more susceptible to the distinction of the
parameter coefficients. However, the general adherence to the linear relationships
observed in most examples implies that the form of Equation 1 is accurate for this
purpose with the possible exception of SI in Sections 3.2.2 and 3.2.4.
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Figure 8 Linear regression of μ. Comparisons between CV values and ε/||Δ||2 terms to provide parameter
specific values for μ.
Table 11 μ values from the various analyses
Analysis Parameter μ
Section 3.1.2 nL 0.560
nK 0.801
Section 3.1.3 nT 0.081
VP 0.683
Section 3.2.1 SI 1.48
VG 2.41
Sections 3.2.2 and 3.2.4 SI 6.45
pG 26.0
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The method presented was able to predict and explain the parameter identifiability
behaviour exhibited in models of insulin kinetics and insulin/glucose dynamics. This
capability is in direct contrast to the traditional derivative-based identifiability analysis
[1,3,11-13] that can only provide a confirmation of an infinitesimal distinction of the
parameters in the governing equations. In addition to the ability to predict parameter
identifiability, the method has been shown to be able to aid sample selection and
explain the non-identifiability of the pG term in common insulin sensitivity tests for IR
participants of dynamic tests. It was also used to derive and justify a novel protocol to
make this parameter more identifiable in this subgroup. Furthermore, the method also
accurately predicted sample redundancy.
Like the proposed method, the method proposed by Raue et al. [4] recognises the
ability of apparently identifiable parameters to become practically non-identifiable in
t h ep r e s e n c eo fa s s a ye r r o ra n ddiscrete sampling. The Raue et al. method requires
numerous simulations and parameter identification processes to characterise the model
sensitivity to variations in each model parameter. In contrast, the proposed method
allows a quick graphical analysis, which can produce immediately apparent and intui-
tive results. Furthermore, the proposed method can quickly appraise protocol variants,
and provide indications of the reason for practical non-identifiability. The method of
Raue et al. is a more general method as it can appraise most model configurations,
whereas the proposed method is currently limited to models with two separable
parameters.
In reality, many models utilise more than two parameters to describe physiological
kinetics and seek to identify all at once. It is expected that development of the pro-
posed method will enable identifiability analyses of such models. However, more care
must be taken to construct the coefficient integral formulations as combinations of
parameters that may come into conflict. This task would require the contrast between
the most deleterious combinations of integral coefficients to be measured. However,
this point was not explored in this study,a st h eg o a lw a st oi n t r o d u c et h eo v e r a l l
approach.
Only cases with separable parameters in terms of measured species were analysed. In
reality, some model parameters are intrinsically linked and this method will not work.
An example of linked parameters would be insulin sensitivity and insulin effect satura-
tion that requires a Michaelis-Menten formulation. In addition, some parameters effect
remote, un-measured concentrations or mas s e sa n da r et h u sn o ta b l et ob ei d e n t i f i e d
with this method. For example, the nC term in Equation 3 could not be evaluated for
identifiability using this method without the inclusion of measurements of interstitial
insulin [26]. As such, this method should not replace the traditional identifiability ana-
l y s i s ,b u tb eu s e di nt a n d e mw i t hi t( o rm e t h o d ss u c ha sR a u eet al. [ 4 ]o rs i m i l a r )t o
produce both theoretical and practical investigations of identifiability.
Furthermore, the model assumes that an expected range of parameter values is
known prior to the commencement of the clinical study. This knowledge is important,
as the method requires that species simulations are available to define the coefficients
of the parameters. However, in most cases, the researcher will be able to obtain an
indication of the likely range of parameter values in a cohort from a brief literature
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clinical testing.
There is also an assumption that the model captures all of the dynamics of the sys-
tem perfectly. In reality no model can provide such accuracy. In particular, Figures 4,
5, 6, 7 show a sample taken at t = 10 for glucose. In reality, this sample will be affected
h e a v i l yb ye r r o rc a u s e db yi n c o m p l e t em i x ing, and although the method presented
indicates that this is a valuable sample, if it is used in the glucose pharmacodynamic
model of Equation 5, the resultant parameters will be overly influenced by an un-mod-
elled mixing effect.
Although the method has limitations and potential for improvement, it can provide
valuable information at a study design stage, as well as valuable identifiability informa-
tion not available from typical methods. It can differentiate between the applicability of
different dynamic tests based on cohorts, and also help to define optimal sample tim-
ing and frequency. In particular, it explained the observation of poor parameter con-
vergence in the Minimal Model for insulin resistant participants that has been widely
reported but without clearly defining the cause. Thus, despite the method’s limitations,
it should still be used in the design stage of a study to ensure that the resultant clinical
data can provide usable results, and time and money is not wasted.
Finally, the method has highlighted the limitation of discrete binary identifiability
analyses as providing potentially misleading assurances of parameter identifiability in
real clinical applications, and shown that identifiability is instead a continuous artefact
of sample timing and the distinction between parameter coefficients.
Appendix 1: Structural identifiability
A1.1 Structural identifiability of the insulin model
Using the method of algebraic derivative approach of [21] and refined in [1] the iden-
tifiability of the model can be confirmed. Using the ranking:
[UN < UX < ˙ UN < ˙ UX < Y < ˙ Y < ¨ Y < I < Q < ˙ I < ˙ Q]
generates the characteristic set of Equations 2 and 3.
−
n2
I
VPVQ
Y +
 
nC +
nI
VQ
  
˙ Y + nKY + nL
Y
1+αY
+
nI
VP
Y +
UX
VP
+ xL(UN)
 
...
...+ ¨ Y + nK ˙ Y + nL
˙ Y
1+α ˙ Y
+
nI
VP
˙ Y +
˙ UX
VP
+ xL( ˙ UN)
(3a)
˙ Y + nKY + nL
Y
1+αY
+
nI
VP
(Y − Q)+
UX
VP
+ xL(UN) (2b)
if: Y = I
Thus, the following coefficients can be defined:
˙ Y :( nC + nK +
nI
VP
+
nI
VQ
) Y :
 
nK +
nI
VP
  
nC +
nI
VQ
 
−
n2
I
VPVQ
˙ Y
1+α ˙ Y
: nL
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)
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1
VP
UX :
1
VP
(nC +
nI
VQ
)
˙ UN : xL UN : xL(nC +
nI
VQ
)
Using arbitrary values for the coefficients confirms global identifiability of the insulin
kinetic model of Equations 2 and 3.
A1.2 Structural identifiability of the glucose model
The structural identifiability of the glucose model is considerably less complex than the
insulin kinetic model. In particular, the characteristic set is defined:
˙ G + pG(G − Gb)+SI(GQ − GbQb) −
PX
VG (4a)
and thus the coefficients are defined:
G : pG GQ : SI
PX :1 /VG Qb : GbSI
and observation confirms that pG, SI, Gb and VG a r eg l o b a l l yi d e n t i f i a b l eu s i n gd e r i -
vative-based identifiability analysis.
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